ArticleEpidemiology and infection2016
Achromobacter xylosoxidans is the predominant Achromobacter species isolated from diverse non-respiratory samples.
Article in Epidemiology and infection, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Early and matureBiofilm · 2026Article
- Establishment of a chinchilla model ofMicrobiology spectrum · 2026Article
- Epidemiology ofNew microbes and new infections · 2026Article
- Analysis of virulence of the emerging opportunistic human pathogen Achromobacter in a zebrafish embryo model.BMC microbiology · 2026Article
- Reversible Secondary Carnitine Deficiency Associated With ChronicClinical medicine insights. Case reports · 2026Article
- Where Do Milk Microbes Originate? Traceability of Microbial Community Structure in Raw Milk.Foods (Basel, Switzerland) · 2025Article
- Comparative phenotypic and genotypic antimicrobial susceptibility surveillance inMicrobiology spectrum · 2025Article
- Development of a Simple and Accurate Molecular Protocol Using 16SrRNA for Species-Specific Identification ofPathogens (Basel, Switzerland) · 2025Article
- Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains.Annals of clinical microbiology and antimicrobials · 2024Article
- Effects of genetic and environmental variables on biofilm development dynamics inIranian journal of microbiology · 2023Article
- Myxinidin-Derived Peptide against Biofilms Caused by Cystic Fibrosis Emerging Pathogens.International journal of molecular sciences · 2023Article
- An 18-Year Dataset on the Clinical Incidence and MICs to Antibiotics ofAntibiotics (Basel, Switzerland) · 2022Article
- Chronic osteomyelitis caused byIDCases · 2021Article
- Review
- Longitudinal Surveillance and Combination Antimicrobial Susceptibility Testing of Multidrug-ResistantAntimicrobial agents and chemotherapy · 2020Article
- Duplex real-time PCR assay for the simultaneous detection ofMicrobial genomics · 2020Article
- Microbial Community Distribution and Core Microbiome in Successive Wound Grades of Individuals with Diabetic Foot Ulcers.Applied and environmental microbiology · 2020Article
- First Documented Case of Percutaneous Endoscopic Gastrostomy (PEG) Tube-Associated Bacterial Peritonitis due toCase reports in gastrointestinal medicine · 2020Article
- [Eradication of Achromobacter spp. multiresistente with colistin otic in patient with chronic otitis media suppurated].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2019Article
- Achromobacter xylosoxidans Infections after Prostate Biopsies, France, 2014.Emerging infectious diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Achromobacter spp. are emerging opportunistic Gram-negative rods responsible for diverse nosocomial or community-acquired infections. We describe, for the first time, the distribution of Achromobacter spp., defined by nrdA gene sequencing, and their antimicrobial susceptibility in a variety of non-respiratory samples recovered from hospitalized patients from 2010 to 2015. Of the 63 isolates studied, A. xylosoxidans was the most prevalent (41 isolates), and with the exception of A. insuavis (four isolates), the remaining 10 species identified were represented by one or two isolates only. All isolates were uniformly susceptible to piperacillin and piperacillin-tazobactam and 97% to meropenem, but 76% showed resistance to ciprofloxacin. This study confirms the diversity of Achromobacter spp. in non-cystic fibrosis (CF) isolates and the predominance of A. xylosoxidans, as previously reported for CF sputum isolates. There was no apparent link between the clinical site of infection and the species of Achromobacter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.